Status and phase
Conditions
Treatments
About
This study determines whether high dose vitamin C is effective for quality of life in terminal cancer patients.
Full description
The investigator's project is a single medical center, randomized double- blinded trial. The target group is terminal cancer patients at Palliative care clinics. The experimental group will receive intravenous high-dose vitamin C 30 g in 500 ml normal saline in 1-hour infusion, once per week, and total 4-week treatment. The control group will receive 500 ml normal saline in 1-hour infusion, once per week, and total 4-week treatment. The primary outcome is the improvement of quality of life, measured by European Organization for Research and Treatment of cancer (EORTC). The secondary outcome is the survival analysis.The participants will be followed up weekly for 2 weeks, then bi-weekly for 6 months.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
-Terminal colon cancer patients without pleural effusions, who will not receive any curative radiotherapy or chemotherapy.
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
40 participants in 2 patient groups, including a placebo group
Loading...
Central trial contact
Chin-Ying Chen, MD, MHSc
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal